10x Genomics (NASDAQ:TXG) Price Target Lowered to $18.00 at Barclays

10x Genomics (NASDAQ:TXG) had its price objective cut by Barclays from $19.00 to $18.00 in a research note published on Monday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other research analysts have also recently issued reports on the company. The Goldman Sachs Group lowered their price objective on 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research note on Wednesday, October 30th. UBS Group dropped their price target on shares of 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. Citigroup reduced their price objective on shares of 10x Genomics from $35.00 to $23.00 and set a “buy” rating for the company in a research note on Wednesday, October 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, February 1st. Finally, JPMorgan Chase & Co. cut their price target on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $23.79.

10x Genomics Stock Performance

TXG stock opened at $12.06 on Monday. The firm has a 50 day moving average price of $14.98 and a 200-day moving average price of $17.56. 10x Genomics has a 52-week low of $11.90 and a 52-week high of $51.22. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -7.88 and a beta of 1.85.

Hedge Funds Weigh In On 10x Genomics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. KBC Group NV raised its stake in shares of 10x Genomics by 38.8% in the third quarter. KBC Group NV now owns 3,225 shares of the company’s stock worth $73,000 after buying an additional 902 shares during the period. Atria Wealth Solutions Inc. increased its holdings in 10x Genomics by 9.6% in the 4th quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company’s stock worth $155,000 after acquiring an additional 943 shares in the last quarter. First Horizon Advisors Inc. raised its stake in 10x Genomics by 53.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company’s stock worth $66,000 after acquiring an additional 1,012 shares during the period. Blue Trust Inc. lifted its holdings in 10x Genomics by 136.5% during the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after purchasing an additional 1,025 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in 10x Genomics by 451.8% during the third quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after purchasing an additional 1,265 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.